Treatment of lupus using humanized anti-cxcr5 antibodies

Abstract

This disclosure provides anti-CXCR5 antibodies and their use in the amelioration, treatment, or prevention of lupus. The disclosure also provides prophylactic, immunotherapeutic, and diagnostic compositions comprising an anti-CXCR5 antibody, and the use of such anti-CXCR5 antibodies in methods of preventing or treating lupus in mammals, including humans.

1 . A method of treating lupus in a patient, comprising administering to the patient a therapeutically effective amount of an antibody or fragment thereof that specifically binds to the extracellular domain of human C-X-C Motif Chemokine Receptor 5 (CXCR5), wherein the antibody or fragment thereof comprises:
 (a) a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 11, and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 12;   (b) the amino acid sequences of RSSKSLLHSSGKTYLY (SEQ ID NO: 58), RMSNLAS (SEQ ID NO: 59), MQHLEYPYT (SEQ ID NO: 60), GFSLIDYGVN (SEQ ID NO: 61), VIWGDGTTY (SEQ ID NO: 62), and IVY (SEQ ID NO: 63):   (c) a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15, and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 16;   (d) the amino acid sequences of RSSKSLLHSSGKTYLY (SEQ ID NO: 58), RLSNLAS (SEQ ID NO: 64), MQHLEYPYT (SEQ ID NO: 60), GFSLIDYGVN (SEQ ID NO: 61), VIWGDGTTY (SEQ ID NO: 62), and IVY (SEQ ID NO: 63);   (e) the amino acid sequences of RSSKSLLHSSGKTYLY (SEQ ID NO: 58), RLSSNLAS (SEQ ID NO: 65), MQHLEYPYT (SEQ ID NO: 60), GFSLIDYGVN (SEQ ID NO: 61), VIWGDGTTY (SEQ ID NO: 62), and IVY (SEQ ID NO: 63);   (f) a variable light chain (VL) comprising the amino acid sequence of SEQ ID NO: 17, SEQ ID NO: 19, or SEQ ID NO: 21, and a variable heavy chain (V H ) comprising the amino acid sequence of SEQ ID NO: 23;   (g) a variable light chain comprising the amino acid sequence of SEQ ID NO: 30, SEQ ID NO: 31, or SEQ ID NO: 32, and a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 33 or SEQ ID NO: 34;   (h) the amino acid sequences of RSSKSLLHSSGKTYLY (SEQ ID NO: 58), RMSNLA (SEQ ID NO: 66), MQHLEYPYT (SEQ ID NO: 60), GFSLIDYGVN (SEQ ID NO: 61), VIWGDGTTY (SEQ ID N: 62), and IVY (SEQ ID NO: 63);   (i) the amino acid sequences of RSSKSLLHSSGKTYLY (SEQ ID NO: 58), RLSNLA (SEQ ID NO: 67), MQHLEYPYT (SEQ ID NO: 60), GFSLIDYGVN (SEQ ID NO: 61), VIWGDGTTY (SEQ ID NO: 62), and IVY (SEQ ID NO: 63);   (j) the amino acid sequences of RSSKSLLHSSGKTYLY (SEQ ID NO: 58), RLSSLA (SEQ ID NO: 68), MQHLEYPYT (SEQ ID NO: 60), GFSLIDYGVN (SEQ ID NO: 61), VIWGDGTTY (SEQ ID NO: 62), and IVY (SEQ ID NO: 63);   (k) a variable light chain comprising the amino acid sequence of SEQ ID NO: 35, and a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 37;   (l) a variable light chain comprising the amino acid sequence of SEQ ID NO: 39, SEQ ID NO: 41, or SEQ ID NO: 43, and a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 45 or SEQ ID NO: 47;   (m) a variable light chain comprising the amino acid sequence of SEQ ID NO: 55, and a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 56 or SEQ ID NO: 57; or   (n) the amino acid sequences of RSSKSLLHSSGKTYLYW (SEQ ID NO; 69), RMSNLA (SEQ ID NO: 66), MQHLEYPYT (SEQ ID NO: 60), GFSLIDYGVN (SEQ ID NO: 61), VIWGDGTTY (SEQ ID NO: 62), and IVY (SEQ ID NO: 63); and   wherein the antibody or fragment thereof is administered every four weeks.   
     
     
         2 . A method of treating lupus in a patient, comprising administering to the patient a therapeutically effective amount of an antibody or fragment thereof that specifically binds to the extracellular domain of human CXCR5, wherein the antibody or fragment thereof comprises a variable light chain comprising the amino acid sequence of SEQ ID NO: 32, and a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 33; and
 wherein the antibody or fragment thereof is administered every four weeks.   
     
     
         3 . A method of treating lupus in a patient, comprising administering to the patient a therapeutically effective amount of an antibody or fragment thereof that specifically binds to the extracellular domain of human CXCR5, wherein the antibody or fragment thereof comprises the amino acid sequences of RSSKSLLHSSGKTYLY (SEQ ID NO: 58), RLSSLA (SEQ ID NO: 68), MQHLEYPYT (SEQ ID NO: 60), GFSLIDYGVN (SEQ ID NO: 61), VIWGDGTTY (SEQ ID NO: 62), and IVY (SEQ ID NO: 63); and
 wherein the antibody or fragment thereof is administered every four weeks.   
     
     
         4 . The method of  claim 1 , wherein the antibody or fragment thereof further comprises one or more constant region domains. 
     
     
         5 . The method of  claim 1 , wherein the antibody or fragment thereof further comprises a C H1 , C H2 , C H3 , or combinations thereof. 
     
     
         6 . The method of  claim 4 , wherein the one or more constant region domains are from an IgG antibody. 
     
     
         7 . The method of  claim 6 , wherein the IgG antibody is an IgG4 antibody. 
     
     
         8 . The method of  claim 1 , wherein the antibody or fragment thereof is a single chain Fv antibody. 
     
     
         9 . The method of  claim 1 , wherein the antibody or fragment thereof is administered to the patient subcutaneously. 
     
     
         10 . The method of  claim 1 , wherein the patient has an anti-dsDNA antibody titer of at least 11 IU/mL. 
     
     
         11 . The method of  claim 1 , wherein the patient has a systematic lupus ertyhematosus disease activity index of at least 4. 
     
     
         12 . The method of  claim 2 , wherein the antibody or fragment thereof is administered to the patient subcutaneously. 
     
     
         13 . The method of  claim 3 , wherein the antibody or fragment thereof is administered to the patient subcutaneously. 
     
     
         14 . The method of  claim 2 , wherein the patient has an anti-dsDNA antibody titer of at least 11 IU/mL. 
     
     
         15 . The method of  claim 3 , wherein the patient has an anti-dsDNA antibody titer of at least 11 IU/mL. 
     
     
         16 . The method of  claim 2 , wherein the patient has a systematic lupus ertyhematosus disease activity index of at least 4. 
     
     
         17 . The method of  claim 3 , wherein the patient has a systematic lupus ertyhematosus disease activity index of at least 4.